Table 3 Summary of significant polymorphisms associated with susceptibility to P-CAP in cases compared to healthy controls

IL10

rs3024498

G

0.21

0.21

0.95 (0.65–1.41)

0.81

IL10

rs3024509

C

0.07

0.09

1.42 (0.81–2.5)

0.23

IL12B

rs730691

T

0.37

0.39

1.02 (0.74–1.4)

0.92

IL4

rs2227284

A

0.25

0.29

1.12 (0.78–1.59)

0.55

ILR1

rs13020778

C

0.47

0.46

1.02 (0.75–1.38)

0.93

ILR1

rs2160227

A

0.32

0.31

1.03 (0.74–1.44)

0.86

ILR1

rs3917254

A

0.14

0.14

1.03 (0.64–1.65)

0.91

ILR1

rs3917267

A

0.36

0.35

0.92 (0.67–1.27)

0.62

NFKBIA

rs1050851

A

0.19

0.23

1.41 (0.97–2. 05)

0.07

NFKBIA

rs696

A

0.43

0.34

0.61 (0.44–0.85)

0.005

NFKBIE

rs2282151

C

0.19

0.21

1.08 (0.74–1.58)

0.69

NFKBIE

rs730775

G

0.49

0.50

1.09 (0.8–1.5)

0.58

NFKBIZ

rs11718446

A

0.26

0.25

1 (0.69–1.45)

0.99

NKFBIZ

rs645781

C

0.25

0.27

1.07 (0.75–1.55)

0.7

NFKBIZ

rs677011

G

0.36

0.38

1.07 (0.77–1.48)

0.7

NFKBIZ

rs9841857

T

0.27

0.24

0.82 (0.57–1.19)

0.3